Halozyme Therapeutics, Inc. (HALO)

Halozyme Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Nov 21, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	5,814	4,882	7,694	5,659	5,765	2,591
Market Cap Growth	43.89%	-36.54%	35.96%	-1.84%	122.48%	23.18%
Enterprise Value	6,683	5,929	8,940	5,722	5,817	2,425
Last Close Price	45.70	36.96	56.90	40.21	42.71	17.73
PE Ratio	15.12	17.60	39.51	14.68	46.93	-
Forward PE	9.86	9.77	21.92	17.89	25.20	163.86
PS Ratio	6.15	5.89	11.65	12.76	21.54	13.22
PB Ratio	12.84	58.26	45.31	28.73	38.16	28.24
P/TBV Ratio	-	-	-	28.73	38.16	28.24
P/FCF Ratio	14.81	13.08	32.70	18.99	108.87	-
P/OCF Ratio	14.43	12.56	32.04	18.90	103.95	-
PEG Ratio	0.40	0.40	0.40	0.45	0.55	-
EV/Sales Ratio	7.05	7.15	13.54	12.91	21.74	12.37
EV/EBITDA Ratio	12.08	14.22	26.60	20.63	39.89	-
EV/EBIT Ratio	14.01	17.43	30.89	20.74	40.33	-
EV/FCF Ratio	17.02	15.88	37.99	19.20	109.86	-
Debt / Equity Ratio	3.39	18.27	9.07	4.47	2.66	4.46
Debt / EBITDA Ratio	2.73	3.59	4.54	3.15	2.71	-
Debt / FCF Ratio	3.91	4.10	6.55	2.95	7.59	-
Asset Turnover	0.47	0.46	0.45	0.53	0.47	0.39
Inventory Turnover	1.92	2.36	2.67	2.04	1.72	7.17
Quick Ratio	8.75	5.07	4.54	7.10	1.11	5.61
Current Ratio	10.36	6.64	5.65	7.91	1.32	6.35
Return on Equity (ROE)	111.83%	222.07%	110.23%	231.44%	106.33%	-42.41%
Return on Assets (ROA)	14.87%	11.89%	12.28%	20.48%	15.74%	-8.40%
Return on Capital (ROIC)	15.83%	12.78%	12.98%	21.16%	17.11%	-9.65%
Earnings Yield	6.75%	5.77%	2.63%	7.12%	2.24%	-2.79%
FCF Yield	6.75%	7.65%	3.06%	5.27%	0.92%	-3.45%
Buyback Yield / Dilution	4.66%	4.56%	4.22%	-3.77%	1.99%	-0.51%
Total Shareholder Return	4.66%	4.56%	4.22%	-3.77%	1.99%	-0.51%

Source: S&P Capital IQ. Standard template. Financial Sources.